Search results - 13 results
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
(2023) Keywords: Alpha COVID-19 Delta Vaccine effectiveness Health Topics: Acute respiratory tract infection Acute luchtweginfectie Infection respiratoire aiguë Service: Maladies virales Virale ziekten ...
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions.
Mycoplasma and Chlamydia Infections (ESGMAC), and the ESGMAC Mycoplasma pneumoniae Surveillance (MAPS) study group Source: Lancet Microbe (2023) Health Topics: Acute respiratory tract infection Acute ...
Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022.
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in early 2020 and subsequent implementation of public health and social measures (PHSM) disrupted the epidemiology of respiratory viruses. This work describes the ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022.
Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose. Health Topics: Acute ...
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.
a first booster dose during the latter period increased VE to over 90%. Health Topics: Acute luchtweginfectie Acute respiratory tract infection Infection respiratoire aiguë Service: Épidémiologie des ...
Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions
Rama; Kociolek, Larry K; Kies, Kami D; Mainella, Jill; Kapinos, Jessica; Patel, Robin; Rodríguez, Nadia; Lorenz, David; Blakiston, Matthew R; Bossuyt, Nathalie Source: The Lancet Microbe (2023) Health ...
Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020.
treatment given within 48 hours and possibly up to 7 days after symptom onset reduced risk of in-hospital death. NAI treatment should be considered in older patients to prevent severe outcomes. Health ...
Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?
Source: Lancet Microbe, Volume 3, Issue 12 (2022) Keywords: Antibodies, Bacterial COVID-19 Humans Mycoplasma pneumoniae Pandemics Pneumonia, Mycoplasma Health Topics: Acute respiratory tract infection ...
Sentinel SARI surveillance in Belgium in times of COVID-19 pandemic
Barbezange Source: OPTIONS XI for the Control of Influenza, ISIRV, Belfast, United-Kingdom (2022) Health Topics: Acute respiratory tract infection Acute luchtweginfectie Infection respiratoire aiguë Influenza ...
Was SARI surveillance successful at monitoring SARS-CoV-2 circulation and its genomic evolution in Belgium throughout the pandemic?
Nathalie Bossuyt; François Dufrasne; Cyril Barbezange Source: OPTIONS XI for the Control of Influenza, ISIRV, Belfast, United-Kingdom (2022) Keywords: SARI surveillance Health Topics: Acute respiratory ...